Roche to Present Over 30 Abstracts Across 10 Cancer Types at ESMO Congress 2025

Strategic Insights -

Roche, a global leader in oncology, announced today that it will present more than 30 abstracts across 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17-21. The data showcase Roche's commitment to delivering transformative medicines for some of the most challenging cancer types, including breast, lung, and gastrointestinal cancers.

Key Takeaways:

  • Roche will present primary results from the phase III evERA Breast Cancer study, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer treated with giredestrant and everolimus.
  • The company will also present results from the IMvigor011 trial, a phase III study pioneering a circulating tumour DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer, showing statistically significant and clinically meaningful improvements in disease-free survival and overall survival.
  • Roche will present final OS data from the pivotal ALEX study of Alecensa, an established first-line treatment and standard of care for people with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
  • The company will also present updated results from the phase III ALINA study, reinforcing the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC.

Statistics:

  • Over 30 abstracts will be presented across 10 cancer types at ESMO Congress 2025.
  • The phase III evERA Breast Cancer study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in 37% of patients treated with giredestrant and everolimus (co-primary ESR1-mutated population) and 49% of patients with detectable ctDNA (secondary endpoint).
  • The IMvigor011 trial showed a statistically significant and clinically meaningful improvement in disease-free survival in 54% of patients treated with Tecentriq (atezolizumab) and a lack of detectable ctDNA, and 47% of patients with detectable ctDNA at 12 months.
  • The ALEX study demonstrated a 53% reduction in the risk of death among patients treated with Alecensa (alectinib) compared to those treated with crizotinib.
  • The ALINA study showed a 34% reduction in the risk of recurrence in patients treated with Alecensa compared to those treated with chemotherapy.

Sources:

  • Mayer E, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA16.
  • Powles T, et al. IMvigor011: a phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA8.
  • Mok T, et al. Final overall survival (OS) and safety analysis of the phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA73.